Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02782065 · ClinicalTrials.gov registry record
Validation of the Hospital Asthma Severity Score (HASS)
A clinical trial, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- 58
- Enrollment target
NCT02782065: Completed study, sponsored by Boston Children's Hospital.
NCT02782065 is a clinical trial that has completed, run by Boston Children's Hospital. The registered enrollment target is 58 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02782065 has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- 58 participants
- Enrollment target
Study Summary
The purpose of this research will be to evaluate the reliability and validity of the HASS tool in a cohort of patients' ages 7 to18 years old against the gold standard of spirometry, and in ages 2 to 6 against spirometry, if possible, and the most similar validated tool, the PRAM.
Primary Outcome
The inter-rater reliability (the percent of agreement among raters) for the HASS as scored by 2 individual health care providers. Inter-rater agreement refers to the agreement between the single clinician who was Rater 1 and the second clinician rating the patient (Rater 2), regardless of which clinician served as Rater 2
Interventions
- OTHER Not an interventional study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2016-09-29 |
| Est. Completion | 2020-01 |
What the finished NCT02782065 record still lists
NCT02782065 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 58 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Not an interventional study is the first listed.
NCT02782065 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02782065 about?
NCT02782065 is a clinical study titled "Validation of the Hospital Asthma Severity Score (HASS)". The purpose of this research will be to evaluate the reliability and validity of the HASS tool in a cohort of patients' ages 7 to18 years old against the gold standard of spirometry, and in ages 2 to 6 against spirometry, if possible, and the most similar validated tool, the PRAM.
What is the current status of trial NCT02782065?
This trial is currently completed. The enrollment target is 58 participants. The study started on 2016-09-29. Estimated completion is 2020-01.
What interventions are being tested in trial NCT02782065?
The interventions under investigation include: Not an interventional study (OTHER).
Who is sponsoring clinical trial NCT02782065?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI